| |
Gender
|
HIV
|
Previous treatment of TB
|
Total
|
|---|
|
M. tb status
|
M
|
F
|
Unk
|
p value
|
Pos
|
Neg
|
Unk
|
p value
|
Yes
|
No
|
Unk
|
p value
|
|---|
|
Susceptible
|
55 71.4 %
|
49 79.0 %
|
11 (68.7)
|
0,33
|
29 66.0 %
|
20 71.4 %
|
66 79.6 %
|
0,80
|
73 72.2 %
|
33 80.5 %
|
9 69.2 %
|
0,02
|
115 74.2 %
|
|
MDR-TB
|
12 15.6 %
|
10 16.2 %
|
3 (18.8)
|
11 25.0 %
|
5 17.9 %
|
9 (10.8)
|
20 19.8 %
|
4 9.8 %
|
1 7.7 %
|
25 16.1 %
|
|
R-mono resistant
|
2 2.6 %
|
0
|
0 (0.0)
|
1 2.2 %
|
0
|
1 1.2 %
|
1 1.0 %
|
1 2.4 %
|
0
|
2 1.3 %
|
|
H-mono resistant
|
8 10.4 %
|
3 4.8 %
|
2 (12.5)
|
3 6.8 %
|
3 10.7 %
|
7 8.4 %
|
7 7.0 %
|
3 7.3 %
|
3 23.1 %
|
13 8.4 %
|
|
Total
|
77
|
62
|
16
| |
44
|
28
|
83
| |
101
|
41
|
13
| |
155 100 %
|
-
M. tb Mycobacterium tuberculosis, M male, F female, Unk unknown, Pos positive, Neg negative, MDR-TB isolates resistant to rifampicin and isoniazid, R-mono resistant only to rifampicin, H-mono resistant only to isoniazid
-
Chi-square and Fisher comparing susceptible and non-susceptible groups. Significance p < 0.05
